Disc Medicine COO receives option and RSU awards

Disc Medicine Chief Operating Officer Yu Jonathan Yen-Wen reported equity awards in the form of restricted stock units and stock options.

Rhea-AI Filing Summary

Disc Medicine Chief Operating Officer Yu Jonathan Yen-Wen reported equity awards in the form of restricted stock units and stock options. He acquired 17,000 shares of Common Stock as RSUs at $0 per share, bringing his direct Common Stock holdings to 57,555 shares.

He was also granted a stock option for 25,500 shares with an exercise price of $74.75 per share, with 25,500 derivative securities owned directly after the grant. The RSUs vest in four annual 25% installments starting February 15, 2027, and the option vests in 48 equal monthly installments starting March 10, 2026, in each case subject to his continued service.

Insider Trade Summary

Grant/Award: 42,500 shares

Grant/Award 2 txns

Insider Yu Jonathan Yen-Wen

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	25,500	$0.00	$0.00
Grant/Award	Common Stock	17,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 25,500 contracts (Direct); Common Stock — 57,555 shares (Direct)

Footnotes (2)

1. F1. Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest annually in four 25% installments commencing on February 15, 2027, subject to the Reporting Person's continued service on each such vesting date.
2. F2. The shares underlying this option vest in 48 equal monthly installments commencing on March 10, 2026, subject to the Reporting Person's continued service on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did IRON executive Yu Jonathan Yen-Wen report?

Yu Jonathan Yen-Wen reported receiving equity awards, not an open-market trade. He acquired 17,000 Common Stock shares as restricted stock units and a stock option covering 25,500 shares, all recorded as direct ownership on the transaction date.

How many Disc Medicine (IRON) shares does the COO own after this Form 4?

After the reported grant, Yu Jonathan Yen-Wen directly owns 57,555 shares of Disc Medicine Common Stock. He also directly holds a stock option covering 25,500 additional shares, which represents a separate derivative position with its own vesting and exercise terms.

What are the key terms of the 25,500-share stock option reported by IRON’s COO?

The stock option covers 25,500 Common Stock shares with a conversion or exercise price of $74.75 per share. It vests in 48 equal monthly installments beginning March 10, 2026, and remains subject to the executive’s continued service through each vesting date.

How do the 17,000 Disc Medicine (IRON) RSUs granted to the COO vest?

The 17,000 restricted stock units vest annually in four equal 25% installments. Vesting begins on February 15, 2027, with each installment contingent on Yu Jonathan Yen-Wen’s continued service to the company on each applicable vesting date.

Is the equity reported in this Disc Medicine (IRON) Form 4 a purchase or a grant?

The filing reflects equity grants, not market purchases. Both the 17,000 Common Stock RSUs and the 25,500-share stock option were acquired at a reported price of $0 for the awards themselves, consistent with compensation-related grants.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/11/2026 - 07:34 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yu Jonathan Yen-Wen

(Last) (First) (Middle)

C/O DISC MEDICINE, INC.

321 ARSENAL STREET, SUITE 101

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Disc Medicine, Inc. [ IRON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		A		17,000(1)	A	$0	57,555	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$74.75	02/10/2026		A		25,500		(2)	02/09/2036	Common Stock	25,500	$0	25,500	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest annually in four 25% installments commencing on February 15, 2027, subject to the Reporting Person's continued service on each such vesting date.

2. The shares underlying this option vest in 48 equal monthly installments commencing on March 10, 2026, subject to the Reporting Person's continued service on each such vesting date.

	By: /s/ Rahul Khara, as Attorney-in-Fact	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.